Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC.SI · Entity 5607 | Director | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SHOULDER INNOVATIONS, INC.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,438 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 669 · Balance 7,438 F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 20, 2025
Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Child 1 | 0 |
Reported balance
After 2025-02-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Child 2 | 0 |
Reported balance
After 2025-02-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Child 3 | 0 |
Reported balance
After 2025-02-19 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-02-19 · Other · Disposed 1,550 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2025-02-19 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-02-19 · Other · Disposed 1,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-19 transaction · row 6
2 source rows · reconciled sequenceRow 5 · 2025-02-19 · Grant · Acquired 20,393 · Balance 717,637 F2: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance. Row 6 · 2025-02-19 · Other · Disposed 717,637 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F3: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.00 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-19 · Disposition to issuer · Disposed 36,085 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.44 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-19 · Disposition to issuer · Disposed 44,693 · Balance 0 F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Pursuant to the Merger Agreement, at the Effective Time, these performance-based restricted stock units vested based on deemed achievement of maximum performance.
F3: Includes 149,010 shares of restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F4: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2023 Filed Oct 4, 2023 01:26 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 497 | $65.40 | $32,503.80 |
DisclosureSEC source: 0001127602-23-025402 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,635 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 21:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 595 | $68.03 | $40,477.85 |
DisclosureSEC source: 0001127602-23-022961 · form4.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,132 F1 · shares: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $67.89 to $68.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · balance_after: Includes 199 shares acquired on July 31, 2023, under the Company's Employee Stock Purchase Plan. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 21:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 9,906 | $67.31 | $666,772.86 |
DisclosureSEC source: 0001127602-23-022961 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,727 F1 · shares: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $66.88 to $67.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 21:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 8,009 | $66.32 | $531,156.88 |
DisclosureSEC source: 0001127602-23-022961 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 485,633 F1 · shares: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $65.88 to $66.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 21:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 18,166 | $65.31 | $1,186,421.46 |
DisclosureSEC source: 0001127602-23-022961 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,642 F1 · shares: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.88 to $65.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 22:16 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,006 | $58.14 | $58,488.84 |
DisclosureSEC source: 0001127602-23-020265 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 511,609 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 22:16 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 646 | $58.14 | $37,558.44 |
DisclosureSEC source: 0001127602-23-020265 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,615 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 22:16 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 347 | $58.14 | $20,174.58 |
DisclosureSEC source: 0001127602-23-020265 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,261 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| May 17, 2023 Filed May 19, 2023 00:16 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 51 | $69.19 | $3,528.69 |
DisclosureSEC source: 0001127602-23-016225 · form4.xml · nonDerivative · entry 6 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,608 F1 · shares: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. Read SEC document |
| May 17, 2023 Filed May 19, 2023 00:16 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,630 | $69.19 | $181,969.70 |
DisclosureSEC source: 0001127602-23-016225 · form4.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,659 F1 · shares: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $70.27 to $71.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 17, 2023 Filed May 19, 2023 00:16 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 16,079 | $69.19 | $1,112,506.01 |
DisclosureSEC source: 0001127602-23-016225 · form4.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,289 F1 · shares: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.07 to $69.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:16 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 153 | $70.87 | $10,843.11 |
DisclosureSEC source: 0001127602-23-016225 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 532,368 F1 · shares: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:16 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 16,945 | $70.87 | $1,200,892.15 |
DisclosureSEC source: 0001127602-23-016225 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 532,521 F1 · shares: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $70.27 to $71.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:16 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 818 | $70.87 | $57,971.66 |
DisclosureSEC source: 0001127602-23-016225 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 549,466 F1 · shares: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the distribution and settlement of previously vested Restricted Stock Units (RSUs). The sale to cover transactions were irrevocably agreed to in writing by the Reporting Person prior to the distribution of the RSUs to satisfy the tax withholding obligations and do not represent a discretionary transaction by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.07 to $69.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:09 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 1,006 | $61.74 | $62,110.44 |
DisclosureSEC source: 0001127602-23-012450 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,284 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:09 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 646 | $61.74 | $39,884.04 |
DisclosureSEC source: 0001127602-23-012450 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,290 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:09 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 347 | $61.74 | $21,423.78 |
DisclosureSEC source: 0001127602-23-012450 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,936 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 20:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,800 | $64.73 | $116,514.00 |
DisclosureSEC source: 0001127602-23-010958 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 552,283 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $64.61 to $64.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: Balance includes 171 shares acquired under the Company's Employee Stock Purchase Plan. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 20:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 7,200 | $64.18 | $462,096.00 |
DisclosureSEC source: 0001127602-23-010958 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 554,083 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $63.58 to $64.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 23:08 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionRestricted Stock Unit · Derivative | 430,517 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-010147 · form4.xml · derivative · entry 6 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 430,517 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Amount represents the vesting in full of restricted stock units (RSUs) granted under the 2011 Plan in August 2019 that were subject to achievement of certain conditions specified in the award agreement, including continued service to the company. 100% of the RSUs vested on the fourth anniversary of the vesting commencement date as all conditions were satisfied. F1 · derivative.expiration_date: Amount represents the vesting in full of restricted stock units (RSUs) granted under the 2011 Plan in August 2019 that were subject to achievement of certain conditions specified in the award agreement, including continued service to the company. 100% of the RSUs vested on the fourth anniversary of the vesting commencement date as all conditions were satisfied. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 23:08 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 430,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-010147 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:54 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 9,000 | $55.19 | $496,710.00 |
DisclosureSEC source: 0001127602-23-006508 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,595 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 21:54 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantStock Options (Right to Buy) · Derivative | 36,085 | $56.00 Strike: $56.00 | $2,020,760.00 |
DisclosureSEC source: 0001127602-23-006508 · form4.xml · derivative · entry 7 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,085 Underlying: Common Stock · 36,085 shares Expires 2030-02-17 F4 · derivative.exercise_date: These options were granted on February 18, 2023 under the Inari Medical, Inc. 2020 Incentive Award Plan and are scheduled to become vested and exercisable on a quarterly basis commencing April 1, 2023. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 21:54 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 46,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006508 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,595 F1 · shares: 2023 Annual Restricted Stock Units grant ("RSUs"). Vesting Commencement Date begins January 1, 2023, 1/16th of the RSUs shall vest on each quarterly anniversary of the vesting Commencement Date. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 22:45 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 100 | $62.66 | $6,266.00 |
DisclosureSEC source: 0001127602-23-002143 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,046 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F4 · balance_after: Balance includes 193 shares acquired under the Employee Stock Ownership Plan. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 22:45 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 6,900 | $62.07 | $428,283.00 |
DisclosureSEC source: 0001127602-23-002143 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,146 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $61.60 to $62.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 22:45 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,000 | $61.29 | $122,580.00 |
DisclosureSEC source: 0001127602-23-002143 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,046 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.59 to $61.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 23:41 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 762 | $63.56 | $48,432.72 |
DisclosureSEC source: 0001127602-23-000716 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,853 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 23:41 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 383 | $63.56 | $24,343.48 |
DisclosureSEC source: 0001127602-23-000716 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,615 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 21:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,090 | $69.00 | $282,210.00 |
DisclosureSEC source: 0001127602-22-028160 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,998 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $68.74 to $69.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 21:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,010 | $68.28 | $273,802.80 |
DisclosureSEC source: 0001127602-22-028160 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $67.73 to $68.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 21:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 900 | $67.16 | $60,444.00 |
DisclosureSEC source: 0001127602-22-028160 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,098 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $66.65 to $67.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,989 | $77.90 | $310,743.10 |
DisclosureSEC source: 0001127602-22-026266 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,998 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $77.69 to $78.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:35 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,011 | $77.46 | $388,152.06 |
DisclosureSEC source: 0001127602-22-026266 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,987 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.69 to $77.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 21:20 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 400 | $73.88 | $29,552.00 |
DisclosureSEC source: 0001127602-22-024305 · form4.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,998 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $73.79 to $74.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 21:20 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,565 | $73.14 | $187,604.10 |
DisclosureSEC source: 0001127602-22-024305 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,398 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $72.75 to $73.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 21:20 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,491 | $72.04 | $323,531.64 |
DisclosureSEC source: 0001127602-22-024305 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,963 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $71.75 to $72.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 21:20 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,544 | $71.45 | $110,318.80 |
DisclosureSEC source: 0001127602-22-024305 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,454 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $70.74 to $71.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 21:34 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 646 | $72.64 | $46,925.44 |
DisclosureSEC source: 0001127602-22-023558 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,998 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 21:34 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 347 | $72.64 | $25,206.08 |
DisclosureSEC source: 0001127602-22-023558 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,644 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 21:37 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,000 | $70.00 | $350,000.00 |
DisclosureSEC source: 0001127602-22-022216 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,991 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:30 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 61 | $79.92 | $4,875.12 |
DisclosureSEC source: 0001127602-22-020367 · form4.xml · nonDerivative · entry 4 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,991 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:30 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,604 | $79.19 | $285,400.76 |
DisclosureSEC source: 0001127602-22-020367 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,052 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $78.70 to $79.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:30 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 435 | $77.87 | $33,873.45 |
DisclosureSEC source: 0001127602-22-020367 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,656 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $77.62 to $78.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:30 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 900 | $76.90 | $69,210.00 |
DisclosureSEC source: 0001127602-22-020367 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,091 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.61 to $77.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 22:17 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,000 | $70.31 | $351,550.00 |
DisclosureSEC source: 0001127602-22-019006 · form4.xml · nonDerivative · entry 3 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,991 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:17 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 646 | $68.66 | $44,354.36 |
DisclosureSEC source: 0001127602-22-019006 · form4.xml · nonDerivative · entry 2 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,991 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:17 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 347 | $68.66 | $23,825.02 |
DisclosureSEC source: 0001127602-22-019006 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,637 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:34 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,000 | $70.08 | $350,390.00 |
DisclosureSEC source: 0001127602-22-017136 · form4.xml · nonDerivative · entry 1 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,984 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 02, 2022 Filed May 4, 2022 20:33 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 100 | $81.75 | $8,175.00 |
DisclosureSEC source: 0001562180-22-003739 · primarydocument.xml · nonDerivative · entry 5 Hykes Andrew · CIK 0001806431 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,984 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.